Multiple Myeloma
Multiple Myeloma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
33
Clinical Trials
Multiple Myeloma
Phase III
Accepting Patients
nct/study# NCT03651128 / BB2121-MM-003
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04196491 / BB-2121-MM-004
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4)
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT02773030 / CC-220-MM-001
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04142619 / UCARTS1A
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma
Learn More
Multiple Myeloma
N/A
Accepting Patients
nct/study# NCT04458831 / IONA OBS16577
A Prospective, Non-Interventional, Multinational, Observational Study With Isatuximab In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM)
Learn More
Multiple Myeloma
NA
Accepting Patients
We are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.